Defining the Pharmerging Market: The New Growth Engine of Global Pharma
Description: An introduction to the Pharmerging Market, defining what these countries are, how they are categorized into tiers, and why they have become the most significant drivers of global pharmaceutical growth.
The term Pharmerging Market refers to a group of rapidly developing economies, primarily located in Asia, Latin America, and Eastern Europe, that are characterized by rapid expansion in their pharmaceutical sectors despite having historically lower healthcare spending compared to mature markets. These countries are shifting the global pharmaceutical industry's center of gravity, offering massive patient populations and increasing purchasing power. This phenomenon is driven by structural shifts, making these regions the new epicenter for volume and value growth in medicine.
Industry analysts typically segment the Pharmerging Market into three tiers based on size and growth potential. Tier 1 is dominated by China, the single largest market outside of the US. Tier 2 often includes countries like Brazil, Russia, India, and South Africa (BRIS), which show high growth potential supported by increasing government investment and an expanding middle class. Tier 3 includes nations such as Mexico, Turkey, Indonesia, and other high-potential economies, each presenting unique logistical and regulatory environments for pharmaceutical companies.
The sheer size and velocity of this market transformation are staggering. While mature markets face slower growth due to patent cliffs and cost controls, the pharmerging nations continue to expand rapidly, fueled by large volumes of medicine use. For multinational corporations (MNCs), understanding the nuances of these tiered markets is crucial for drafting effective strategic roadmaps that prioritize regions with the most immediate and long-term potential for expansion and revenue generation.
FAQs
Which countries are typically included in the definition of the Pharmerging Market?
The most commonly cited countries include the BRICS nations (Brazil, Russia, India, China, South Africa) and MIST nations (Mexico, Indonesia, South Korea, Turkey), though the list can encompass 21 or more countries based on various economic and market metrics.
Why are Pharmerging Markets growing faster than mature markets like the US or Europe?
Growth is faster due to a confluence of factors, including rapid economic expansion, increasing disposable incomes, a shift in disease profiles toward chronic non-communicable diseases (NCDs), and lower starting points for pharmaceutical expenditure.